癌症后疼痛的精准医学:CANPPHE网络基于2021年IASP伤害可塑性疼痛标准的国际多学科指南
癌症后疼痛仍被低估和治疗不足。CANPPHE网络是一个来自七个国家的国际跨学科肿瘤临床医生和研究人员小组,应用2021年IASP伤害可塑性疼痛临床标准于日益增长的癌症后疼痛人群,提供了一份手册以区分主要的伤害感受性、神经病理性或伤害可塑性疼痛,并提出了七步诊断方法,通过案例说明以促进临床实施。
要点
- 癌症后疼痛可分为伤害感受性、神经病理性或伤害可塑性疼痛三种主要表型。
- 2021年IASP伤害可塑性疼痛临床标准和分级系统有助于早期识别和分类疼痛表型。
- CANPPHE网络提供了七步诊断方法和手册以助临床医生区分疼痛表型。
核心结论
- 应用2021年IASP伤害可塑性疼痛标准对癌症后疼痛进行表型分类是迈向精准疼痛医学的重要一步。
研究设计与样本
- 国际跨学科小组(CANPPHE网络)来自七个国家,应用2021年IASP临床标准并制定手册。
主要发现
- 伤害可塑性疼痛存在于相当一部分癌症后疼痛患者中。
- 提供了七步诊断方法并辅以案例说明。
关键数值与推荐
- 2021年IASP伤害可塑性疼痛临床标准和分级系统。
- 七步诊断方法用于区分主要疼痛表型。
临床怎么用
- 临床医生可使用提供的手册和七步诊断方法在癌症后疼痛患者中区分伤害感受性、神经病理性或伤害可塑性疼痛。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pain after cancer remains underestimated and undertreated. Precision medicine is a recent concept that refers to the ability to classify patients into subgroups that differ in their susceptibility to, biology, or prognosis of a particular disease, or in their response to a specific treatment, and thus to tailor treatment to the individual patient characteristics. Applying this to pain after cancer, the ability to classify post-cancer pain into the three major pain phenotypes (i.e. nociceptive, neuropathic, and nociplastic pain) and tailor pain treatment accordingly, is an emerging issue. This is especially relevant because available evidence suggests that nociplastic pain is present in an important subgroup of those patients experiencing post-cancer pain. The 2021 International Association for the Study of Pain (IASP) clinical criteria and grading system for nociplastic pain account for the need to identify and correctly classify patients according to the pain phenotype early in their treatment. These criteria are an important step towards precision pain medicine with great potential for the field of clinical oncology. Within this framework, the Cancer Pain Phenotyping (CANPPHE) Network, an international and interdisciplinary group of oncology clinicians and researchers from seven countries, applied the 2021 IASP clinical criteria for nociplastic pain to the growing population of those experiencing post-cancer pain. A manual is provided to allow clinicians to differentiate between predominant nociceptive, neuropathic, or nociplastic pain after cancer. A seven-step diagnostic approach is presented and illustrated using cases to enhance understanding and encourage effective implementation of this approach in clinical practice.
引用
- Nijs J, Lahousse A, Fernández-de-Las-Peñas C, et al. Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria. Br J Anaesth. 2023. PMID: 36702650. doi:10.1016/j.bja.2022.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。